Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSymphony Env. Regulatory News (SYM)

Share Price Information for Symphony Env. (SYM)

Share Price is delayed by 15 minutes
Get Live Data
6.75    0.00 (0.00%)
Bid:
6.00
Ask:
7.50
Spread: 1.50 (25.00%)
Market Cap: £15.95m
SYM Live PriceLast checked at - London Stock Exchange

Intraday Symphony Env. Share Chart

Pre-Close Trading Update

28 Apr 2026 07:00

RNS Number : 1040C
Symphony Environmental Tech. PLC
28 April 2026
 

 

 

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

28 April 2026

 

Symphony Environmental Technologies plc

("Symphony", the "Company" or the "Group")

FY-2025 pre-close trading update and

 

Strong start to FY-2026 - first half profitability

 

Symphony Environmental Technologies plc ("Symphony" or the "Group"); global specialists in technologies that make plastic and rubber products "smarter, safer and sustainable", is pleased to provide the following pre-close trading update for the year ended 31 December 2025 ("FY-2025") and notice of FY-2025 results, together with a trading update for the current year to date.

FY2025 trading update (subject to audit)

Further to the Company's announcement on 17 December 2025, the Board now expects that, as a result of management‑driven strategic change in its Middle East operations, Group revenue for FY-2025 will be higher than previously guided, at approximately £5.7 million, with an adjusted loss before interest, tax, depreciation and amortisation ("adjusted LBITDA") broadly comparable to that incurred in the prior year, at approximately £0.9 million.

Importantly, and as further set out below, sales momentum has not just continued but accelerated during the first four months of FY-2026, running at more than 10 per cent. ahead of the same period last year. Furthermore, margins are also improving due to operational leverage as well as the positive impact of strategic initiatives taken during FY-2025, in particular in the Middle East.

In addition to the above adjusted LBITDA, the following one-off costs were incurred during FY-2025 as well as certain asset provisions will be made to the FY-2025 results:

· Strategic costs of £500,000 primarily in relation to the Middle East but also of certain future corporate initiatives;

· Impairment provision of £468,000 against development costs for the Group's antimicrobial products due to extended South American customer trials and commercial evaluation; and

· Other investment provisions of £107,000.

 

 

The net loss including provisions and strategic costs for FY-2025 is expected to be £2.5 million (FY-2024: £1.3 million).

The Board expects to announce its preliminary results for FY-2025 during the latter half of May.

Outlook

The Board remains focused on margin quality, disciplined cost control and the commercialisation of higher‑value technologies, rather than short‑term volume growth.

That said, it is particularly pleasing that trading in the first four months of 2026 has improved materially. The Group delivered a positive EBITDA in Q1-2026, compared with a loss in the corresponding prior‑year and based on current order patterns, expects to deliver a net profit for H1-2026.

Revenues are currently tracking more than 10 per cent ahead of the same period last year. Confirmed orders have been received across all principal markets, particularly Central America. While the timing of shipments remains subject to customer scheduling and customary operational factors, the Board is encouraged by the visibility and quality of the pipeline now in place, which underpins its confidence in the Group's earnings trajectory.

The Group continues to monitor the evolving geopolitical situation in the Middle East, which to date has not had a material adverse effect on operations.

Enquiries:

Symphony Environmental Technologies Plc

Michael Laurier, CEO

Tel: +44 (0) 20 8207 5900

Ian Bristow, CFO

www.symphonyenvironmental.com

Zeus (Nominated Adviser and Broker)

David Foreman, Emma Burn (Investment Banking)

Tel: +44 (0) 203 829 5000

NOTES TO EDITORS

 

 

About Symphony Environmental

 

 

Symphony's d2w masterbatch technology is added to polyethylene (PE) and polypropylene (PP) products at the manufacturing stage at little or no extra cost, and ensures that if they get into the environment at the end of their useful life they will not create microplastics and lie or float around for decades. https://www.symphonyenvironmental.com/technologies/biodegradable-plastic/ Instead they will safely biodegrade, leaving no microplastics or toxicity.

 

If they get collected during their programmed life they can be recycled with ordinary PE and PP without separation See https://www.biodeg.org/subjects-of-interest/recycling-2/

 

Symphony also supplies a range of plastic technologies under its d2p (designed to protect) brand www.d2p.net to provide protection against insects, viruses, bacteria, fungi, rodents, odours, and fire. 

 

It has also introduced a new product under its NbR brand https://www.symphonyenvironmental.com/natural-biodegradable-resin/ to reduce the amount of fossil-derived material in plastic products.

 

Symphony has a diverse and growing customer-base and has established itself as an international business with over 70 distributors around the world. Products made with Symphony's plastic technologies are now available in nearly 100 countries and in many different product applications. Symphony itself is certified according to ISO9001 and ISO14001.

 

Symphony participates in the Committee work of the British Standards Institute (BSI), the American Standards Organisation (ASTM), the European Standards Organisation (CEN), and the International Standards Organisation (ISO).

 

Further information on the Group can be found at www.symphonyenvironmental.com and twitter @SymphonyEnv

 

See also Symphony on Instagram and Linkedin.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFVDSAIDFIR
Date   Source Headline
19th Nov 20218:24 amRNSExpansion into India
12th Nov 20213:04 pmRNSSmall Cap Awards: ESG Company of the Year
25th Oct 20217:00 amRNSExclusive Distribution Agreement
5th Oct 20219:58 amRNSHolding(s) in Company
24th Sep 20217:00 amRNSEquity subscription and grant of warrants
16th Sep 20217:00 amRNSInterim results
3rd Sep 20217:00 amRNSHealth Canada approves d2p for bread packaging
2nd Aug 20217:30 amRNSNew agreements with Meditech
27th Jul 20213:00 pmRNSHolding(s) in Company
14th Jul 20217:00 amRNSNew expanded FDA approval for d2p food packaging
13th Jul 20217:00 amRNSTrading update
28th Jun 202111:56 amRNSResult of AGM
11th Jun 202110:04 amRNSHolding(s) in Company
9th Jun 20217:00 amRNSPDMR Dealing
3rd Jun 20217:00 amRNSPosting of accounts & notice of AGM
13th May 20217:00 amRNSEU legal challenge update
23rd Apr 20217:32 amRNSd2p anti-microbial technology to protect commuters
13th Apr 20212:40 pmRNSDirector Dealing
1st Apr 20213:23 pmRNSDirector Dealing
31st Mar 20217:00 amRNSPreliminary results
30th Mar 20217:00 amRNSCompletion of 5 year Oxomar study re. d2w
12th Mar 20217:00 amRNSEU legal challenge update
9th Feb 20217:00 amRNSTrading update
21st Dec 20207:00 amRNSEU legal action
30th Nov 20207:00 amRNSPositive Coronavirus Test Results of d2p products
16th Nov 20207:00 amRNSNew d2p product launch
9th Nov 20204:40 pmRNSSecond Price Monitoring Extn
9th Nov 20204:36 pmRNSPrice Monitoring Extension
30th Oct 20207:00 amRNSLaunch of d2p and d2w enhanced drinking straws
20th Oct 20207:00 amRNSCompletion of Eranova project financing
19th Oct 20207:00 amRNSLargest Bakery in Turkey Launches d2w Packaging
9th Oct 20207:00 amRNSExtension of Options
5th Oct 20205:52 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSUK Airport Group introduces d2w biodegradable bag
22nd Sep 20207:00 amRNSCotripal launches d2p and d2w shopping bags
16th Sep 20207:00 amRNSInvestor Meet Company presentation
15th Sep 20207:00 amRNSExercise of warrants
14th Sep 20204:40 pmRNSSecond Price Monitoring Extn
14th Sep 20204:35 pmRNSPrice Monitoring Extension
14th Sep 20207:01 amRNSPositive Coronavirus test results
14th Sep 20207:00 amRNSInterim results
13th Aug 20204:41 pmRNSSecond Price Monitoring Extn
13th Aug 20204:35 pmRNSPrice Monitoring Extension
12th Aug 20204:40 pmRNSSecond Price Monitoring Extn
12th Aug 20204:36 pmRNSPrice Monitoring Extension
4th Aug 20204:09 pmRNSPDMR dealing
29th Jul 20207:00 amRNSExercise of Options/PDMR dealing
28th Jul 20207:00 amRNSExercise of Options
23rd Jul 20207:00 amRNSPositive Bovine Coronavirus Test Results
22nd Jul 20207:00 amRNSExtension of warrants

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.